Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Antibody-drug Conjugate
100%
Chimeric Antigen Receptor T-cell Therapy
100%
Immunoconjugate
100%
Chimeric Antigen Receptor T Cells (CAR-T)
75%
CD19
75%
Targeted Therapy
25%
Durable Response
25%
Duration of Response
25%
Loncastuximab Tesirine
25%
Pyrrolobenzodiazepine
25%
CD19 Targeting
25%
T Cell Targeting
25%
Immunology and Microbiology
Drug Antibody
100%
Chimeric Antigen Receptor T-Cell Therapy
100%
Loncastuximab
100%
Immunoconjugate
100%
CD19
80%
Chimeric Antigen Receptor T-Cell
60%
Antibody Drug Conjugate
20%
Loncastuximab Tesirine
20%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Drug Antibody
100%
Chimeric Antigen Receptor T-Cell Immunotherapy
100%
Loncastuximab
100%
Chimeric Antigen Receptor T-Cell
60%
Antibody-Drug Conjugate
20%
Loncastuximab Tesirine
20%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
100%
Chimeric Antigen Receptor
100%
Drug Antibody
100%
Loncastuximab
100%
Antibody Drug Conjugate
20%
Loncastuximab Tesirine
20%